PTGX – protagonist therapeutics, inc. (US:NASDAQ)
Stock Stats
News
11/10
05:18 pm
ptgx
Low
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
11/7
03:46 pm
ptgx
Low
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
11/7
11:09 am
ptgx
Low
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
11/7
09:41 am
ptgx
Low
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.
11/4
05:38 pm
ptgx
Low
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
11/6/2025
04:05 pm
ptgx
-0.3%
MISS
8/6/2025
04:05 pm
ptgx
-5.4%
MISS
5/6/2025
04:05 pm
ptgx
2.6%
BEAT
2/21/2025
07:00 am
ptgx
-0.8%
BEAT
11/10
04:55 pm
Maintains
Buy
Buy
Citigroup
Low
2.8%
11/10
04:55 pm
Maintains
Buy
Buy
Citigroup
Low
2.8%
11/7
03:08 pm
Maintains
Overweight
Overweight
JP Morgan
Low
0.7%
11/7
10:46 am
Maintains
Overweight
Overweight
Barclays
Low
1.0%
11/7
10:46 am
Maintains
Overweight
Overweight
Barclays
Low
1.0%
11/24
04:01 pm
ptgx
Low
Form 4 Protagonist Therapeutics For: Nov 21 Filed by: PATEL DINESH V PH D
11/19
04:01 pm
ptgx
Low
Form 4 Protagonist Therapeutics For: Nov 17 Filed by: MOLINA ARTURO MD
11/14
04:24 pm
ptgx
Low
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
08:23 am
ptgx
Low
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Deep Track Capital, LP
11/6
04:52 pm
ptgx
Low
Form 10-Q Protagonist Therapeutics For: Sep 30
Show more
Top News Gainers
12/3 Form 4 Protagonist Therapeutics For: Dec 03 Filed by: PATEL DINESH V PH D 70.0%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
Top News Decliners
12/3 Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia -46.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3